AML Screening with AMLplex and AMLplus

One Workflow. Full Insight. Speed up AML testing with BIOTYPE!

Timely genetic analysis is essential for Acute Myeloid Leukemia (AML) diagnostics. According to ELN guidelines, certain mutations should be screened within 3 to 5 days, as their molecular status guides treatment regimen, especially for targeted induction therapy. Given the aggressive nature of AML and the urgency of treatment onset, rapid molecular results can have a decisive impact on patient outcomes.

BIOTYPE’s solutions:

• Mentype^® AMLplex^QS PCR Kit (CE-IVD)
  RNA-based assay, which provides qualitative screening of 11 key gene fusions, including time-critical rearrangements PML::RARA, CBFB::MYH11, RUNX1::RUNX1T1, BCR::ABL1, KMT2Ar and others.
• Coming in 2026: Mentype^® AMLplus Mutation Analysis Kit
  DNA-based assay, designed to detect all actionable time-sensitive mutations, such as hotspot variations in IDH1 and IDH2, FLT3 (ITD, TKD mutations), NPM1 insertions, plus CEBPA bZIP in-frame shifts.

Together, these assays deliver a unique, integrated workflow for initial AML profiling in just 4 hours. It accelerates decision-making and supports comprehensive risk assessment.

Want to learn more or have any questions? Contact us at products@biotype.de!